Vasundhara - 2026 Company Profile, Team & Financials

About Vasundhara

Vasundhara is a publicly listed company based in Hyderabad (India) founded in 1990. Active Pharmaceutical Ingredients are manufactured by Vasundhara in India. The company has 36 employees. Its Indian entity Vasundhara Rasayans Limited reported revenue of ₹38.62 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

Vasundhara was established in 1990 in Hyderabad, India, within the pharmaceutical sector. Active Pharmaceutical Ingredients (APIs) are produced as the core operation, supporting drug manufacturing processes. The company maintains its base in Hyderabad, where production activities are centered. Online presence is provided through the domain vasundhararasayans.in, facilitating industry connections in the region.

Headquarters Hyderabad, India
Employees 36
Stage Public
Sectors
Healthcare
Website vasundhararasayans.in
Legal Name Vasundhara Rasayans Limited
Date of Incorporation 05 Mar, 1987
Jurisdiction Hyderabad, Telangana, India

Operational Areas

Healthcare → Biopharma Outsourcing & Drug Delivery

Key Metrics

Market Cap
₹45.13 Cr
VRL · BSE
Share Price
₹130.10
-8.38% today
Revenue
₹35.72 Cr
FY 2025-26 · +5.1% YoY
EBITDA
₹5.83 Cr
Margin 16.3%
Net Profit
₹5.77 Cr
FY 2025-26 · +36.4% YoY
P/E (TTM)
7.2x
P/B 1.0x
ROE
15.2%
ROCE 20.2%
Debt / Equity
0.08
Interest cover 8.3x
Employee Count
36

Associated legal entities of Vasundhara

Vasundhara operates through Vasundhara Rasayans Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.

Legal entity	Status	Incorporated	Registered in	Revenue (FY 2026)	Employees	Directors	Company page
Vasundhara Rasayans Limited Listed CIN L24110TG1987PLC007242	Active	05 Mar 1987	Hyderabad, Telangana	₹38.6 Cr	36	14	View details

Board of directors of Vasundhara Rasayans Limited (Vasundhara)

Vasundhara Rasayans Limited is the primary company behind Vasundhara. The board of Vasundhara Rasayans Limited currently have 12 directors; the longest-serving is Rajesh Pokerna, appointed in 2005. 11 earlier directors have ceased.

Director	Designation	Appointed	Tenure	Entity
Rajesh Pokerna DIN 00117365	Managing Director	07 Oct 2005	21 yrs 1 mo	Vasundhara Rasayans Limited
Sunil Jain Kumar DIN 00117331	Whole-time director	07 Oct 2005	21 yrs 1 mo	Vasundhara Rasayans Limited
Pravinchandra Majmundar Popatlal DIN 01954981	Director	12 Dec 2005	20 yrs 10 mo	Vasundhara Rasayans Limited
Sanjay Kumar Jain DIN 00357850	Whole-time director	01 Apr 2013	13 yrs 7 mo	Vasundhara Rasayans Limited
Seema Jain DIN 07158382	Whole-time director	30 Mar 2015	11 yrs 7 mo	Vasundhara Rasayans Limited
Pradeep Kumar Jain DIN 07553676	Director	15 Mar 2016	10 yrs 7 mo	Vasundhara Rasayans Limited
Manish Jain DIN 10256296	Director	01 Aug 2023	3 yrs 3 mo	Vasundhara Rasayans Limited
Manish Kumar Jain DIN 00357788	Whole-time director	01 Aug 2023	3 yrs 3 mo	Vasundhara Rasayans Limited
Vinod Kumar Jain DIN 10693974	Director	03 Jul 2024	2 yrs 4 mo	Vasundhara Rasayans Limited
Ashok Kumar Jain DIN 10764230	Director	07 Sep 2024	2 yrs 2 mo	Vasundhara Rasayans Limited
Kodakandla Sudarsanam DIN 10764375	Director	07 Sep 2024	2 yrs 2 mo	Vasundhara Rasayans Limited
Ravi Jain DIN 11720815	Additional Director	28 May 2026	5 mo	Vasundhara Rasayans Limited

IPO & Listings of Vasundhara

Vasundhara is a publicly listed company on the BSE with ticker symbol VRL in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

IPO date16 Jan 2015
Listed onBSE: 538634
Listed entityVasundhara Rasayans Limited
Exchange sectorPharmaceuticals

Financials of Vasundhara

Exchange-reported figures of Vasundhara Rasayans Limited, the listed company behind Vasundhara (BSE: VRL).

Financial Highlights

FY 2025-26 · Standalone

Revenue

₹35.72 Cr

+5.1% YoY

EBITDA

₹5.83 Cr

+42.2% YoY

Profit After Tax

₹5.77 Cr

+36.4% YoY

Net Worth

₹40.88 Cr

+15.0% YoY

Total Assets

₹42.68 Cr

+7.3% YoY

Total Debt

₹1.81 Cr

-57.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	35.72	33.99	37.02	37.94	26.75	22.68	21.28
Revenue growth	+5.1%	-8.2%	-2.4%	+41.8%	+18.0%	+6.6%	-
EBITDA	5.83	4.10	6.44	5.55	2.20	3.11	2.83
EBITDA margin	+16.3%	+12.1%	+17.4%	+14.6%	+8.2%	+13.7%	+13.3%
Profit before tax	7.85	5.75	7.91	7.47	3.03	3.96	3.89
Net profit	5.77	4.23	5.87	5.58	1.89	2.94	2.91
Net profit margin	+16.2%	+12.4%	+15.9%	+14.7%	+7.1%	+13.0%	+13.7%
EPS (₹)	18.22	13.36	18.44	17.59	6.84	9.24	9.40
Balance sheet
Total assets	42.68	39.76	33.88	30.84	22.85	20.35	17.62
Net worth	40.88	35.56	31.94	26.82	21.54	19.87	17.41
Total debt	1.81	4.21	1.95	4.02	1.31	0.00	0.00
Cash & bank	2.53	5.54	9.56	7.74	10.77	0.69	0.81
Net working capital	37.70	34.82	30.32	29.86	21.43	9.63	16.33
Cash flow
Cash from operations	(1.58)	(5.83)	6.03	(6.50)	7.90	0.22	0.36
Cash from investing	2.01	0.46	(1.32)	1.27	1.39	0.16	1.02
Cash from financing	(3.44)	1.35	(2.88)	2.19	0.79	(0.49)	(0.87)

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	6.93	11.89	7.45	8.82	7.56	7.76	8.82	9.78
Revenue growth (YoY)	-8.3%	+53.2%	-15.5%	-9.8%	-0.9%	-	-	-
Other income	0.37	0.69	0.67	0.86	0.68	0.83	0.54	0.53
Total expenses	6.25	9.06	6.94	6.70	7.23	7.75	7.25	8.17
EBITDA	0.68	2.83	0.51	2.12	0.33	0.01	1.57	1.61
EBITDA margin	+9.8%	+23.8%	+6.8%	+24.0%	+4.4%	+0.1%	+17.8%	+16.5%
Depreciation	0.13	0.11	0.11	0.11	0.10	0.10	0.09	0.09
Interest	0.05	0.08	0.10	0.09	0.14	0.08	0.06	0.08
Profit before tax	0.87	3.33	0.97	2.78	0.77	0.66	1.96	1.97
Tax	0.23	0.86	0.25	0.72	0.20	0.21	0.51	0.52

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	6.93	11.89	7.45	8.82	7.56	7.76	8.82	9.78
Revenue growth (YoY)	-8.3%	+53.2%	-15.5%	-9.8%	-0.9%	-	-	-
Other income	0.37	0.69	0.67	0.86	0.68	0.83	0.54	0.53
Total expenses	6.25	9.06	6.94	6.70	7.23	7.75	7.25	8.17
EBITDA	0.68	2.83	0.51	2.12	0.33	0.01	1.57	1.61
EBITDA margin	+9.8%	+23.8%	+6.8%	+24.0%	+4.4%	+0.1%	+17.8%	+16.5%
Depreciation	0.13	0.11	0.11	0.11	0.10	0.10	0.09	0.09
Interest	0.05	0.08	0.10	0.09	0.14	0.08	0.06	0.08
Profit before tax	0.87	3.33	0.97	2.78	0.77	0.66	1.96	1.97
Tax	0.23	0.86	0.25	0.72	0.20	0.21	0.51	0.52

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	35.72	33.99	37.02	37.94	26.75	22.68	21.28
Revenue growth	+5.1%	-8.2%	-2.4%	+41.8%	+18.0%	+6.6%	-
Other income	2.90	2.35	1.94	2.30	1.04	0.99	1.15
Total expenses	29.89	29.89	30.58	32.39	24.55	19.57	18.45
Employee cost	3.28	3.27	3.28	2.60	2.27	3.42	3.49
EBITDA	5.83	4.10	6.44	5.55	2.20	3.11	2.83
EBITDA margin	+16.3%	+12.1%	+17.4%	+14.6%	+8.2%	+13.7%	+13.3%
Depreciation	0.43	0.36	0.26	0.13	0.12	0.05	0.03
Interest	0.45	0.34	0.21	0.25	0.09	0.09	0.06
Profit before tax	7.85	5.75	7.91	7.47	3.03	3.96	3.89
Tax	2.08	1.52	2.04	1.89	0.87	1.02	0.92
Net profit	5.77	4.23	5.87	5.58	1.89	2.94	2.91
Net profit margin	+16.2%	+12.4%	+15.9%	+14.7%	+7.1%	+13.0%	+13.7%
EPS (₹)	18.22	13.36	18.44	17.59	6.84	9.24	9.40

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	3.18	3.18	3.18	3.18	3.18	3.18	3.18
Reserves & surplus	37.70	32.38	28.76	23.64	18.36	16.69	14.23
Shareholders' funds (net worth)	40.88	35.56	31.94	26.82	21.54	19.87	17.41
Secured loans	1.81	4.21	1.95	4.02	1.31	0.00	0.00
Unsecured loans	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total debt	1.81	4.21	1.95	4.02	1.31	0.00	0.00
Total liabilities	42.68	39.76	33.88	30.84	22.85	20.35	17.62
Assets
Gross block	4.03	3.73	3.31	1.48	1.40	1.05	0.63
Net block	2.35	2.48	2.42	0.86	0.91	0.67	0.30
Capital work in progress	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	2.51	2.35	1.16	0.00	0.32	1.12	0.97
Inventories	1.52	1.88	1.73	4.00	2.21	1.41	1.50
Sundry debtors	7.46	4.15	6.22	8.05	7.34	6.17	6.23
Cash & bank balances	2.53	5.54	9.56	7.74	10.77	0.69	0.81
Loans & advances	31.31	26.48	16.15	13.73	3.73	3.99	14.83
Total current assets	42.82	38.05	33.66	33.52	24.05	12.26	23.37
Total current liabilities	5.12	3.23	3.34	3.66	2.62	2.63	7.04
Net working capital	37.70	34.82	30.32	29.86	21.43	9.63	16.33
Total assets	42.68	39.76	33.88	30.84	22.85	20.35	17.62

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	5.54	9.56	7.74	10.77	0.69	0.81	0.31
Net cash from operating activities	(1.58)	(5.83)	6.03	(6.50)	7.90	0.22	0.36
Net cash from investing activities	2.01	0.46	(1.32)	1.27	1.39	0.16	1.02
Net cash from financing activities	(3.44)	1.35	(2.88)	2.19	0.79	(0.49)	(0.87)
Net change in cash	(3.01)	(4.02)	1.83	(3.04)	10.08	(0.12)	0.50
Closing cash	2.53	5.54	9.56	7.74	10.77	0.69	0.81

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
Sales growth	+5.1%	-8.2%	-2.4%	+41.8%	+18.0%	+6.6%	-
EBITDA growth	+42.2%	-36.3%	+16.0%	+152.3%	-29.3%	+9.9%	-
PBT growth	+36.5%	-27.3%	+5.9%	+146.5%	-23.5%	+1.8%	+88.8%
Net income growth	+36.4%	-27.9%	+5.2%	+195.2%	-35.7%	+1.0%	-
Revenue CAGR (3Y)	-2.0%	+8.3%	+17.7%	+21.3%	+10.6%	+11.0%	+11.3%
EBITDA CAGR (3Y)	+1.7%	+23.1%	+27.5%	+25.2%	+24.1%	+27.8%	+19.7%
Profitability & leverage
Net income margin	+16.2%	+12.4%	+15.9%	+14.7%	+8.1%	+13.0%	+14.0%
Return on capital employed	+20.2%	+16.6%	+25.1%	+28.8%	+12.8%	+21.4%	+24.0%
Return on net worth	+15.2%	+12.6%	+20.0%	+23.1%	+9.2%	+15.8%	+18.6%
Debt / equity	0.08	0.09	0.10	0.11	0.03	0.00	0.01
Long-term debt / equity	0.01	0.02	0.01	0.00	0.00	0.00	0.00
Interest cover	8.33	9.09	3.40	4.61	4.33	2.94	2.14
Efficiency & per share
Fixed asset turnover	9.21	9.66	15.46	26.35	21.84	27.00	37.66
Inventory turnover	21.01	18.83	12.92	12.22	14.78	15.59	13.95
Debtors turnover	6.15	6.56	5.19	4.93	3.96	3.66	3.75
EPS (₹)	18.22	13.36	18.44	17.59	6.84	9.24	9.40
Dividend per share (₹)	2.00	2.00	0.00	0.00	1.00	1.50	1.50
Book value per share (₹)	128.61	111.88	100.49	84.38	67.76	62.52	54.78

Similar companies to Vasundhara

Vasundhara has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company Name	Domain	Founded	HQ Location	Total funding	Employees	Description
Laurus Labs	lauruslabs.com	2005	Hyderabad, India	$229.73M	6,035	Pharmaceutical and biotechnology company
Symbiotec	symbiotec.in	2002	Indore, India	$61.01M	1,822	Non-sterile steroid hormone-based APIs and intermediates are manufactured.
SeQuent	sequent.in	2002	Bengaluru, India			APIs are developed and manufactured for therapeutic areas.

Premium access

Detailed similar companies of Vasundhara

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

Full competitor set
Operating metrics
Benchmarks
Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Vasundhara (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

Company	Description	Founded	Location	Total funding	Revenue	Employees
Anthem Biosciences	Developer of integrated contract research development and manufacturing services	2007	Bengaluru, Karnataka, India	USD 35.74 M	USD 226.38 M	2,062
Laurus Labs	Pharmaceutical and biotechnology company	2005	Hyderabad, Telangana, India	USD 229.73 M	USD 726.15 M	12,470
Entero Healthcare	India's leading healthcare products distribution platform	2018	Mumbai, Maharashtra, India	USD 59.67 M	USD 702.49 M	557

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.

Included in your Premium account

✓
Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
✓
Full access to every database India & global coverage, advanced filters and rich profile details
✓
Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Vasundhara

Vasundhara Rasayans standalone net profit rises 14.04% in the June 2026 quarter | Capital Market News - Business Standard

Business Standard • 2 months ago

Vasundhara Ras Standalone December 2024 Net Sales at Rs 8.82 crore, up 7.23% Y-o-Y

Moneycontrol • 1 year ago

Vasundhara Rasayans reports standalone net profit of Rs 2.84 crore in the September 2022 quarter

India Infoline • 1 year ago

Vasundhara Rasayans to conduct board meeting

India Infoline • 1 year ago

Vasundhara Ras Standalone June 2024 Net Sales at Rs 7.63 crore, down 8.45% Y-o-Y

Moneycontrol • 2 years ago

Vasundhara Rasayans resumes operations of the unit

Indiainfoline • 4 years ago

Vasundhara Ras Standalone December 2021 Net Sales at Rs 6.43 crore, up 8.07% Y-o-Y

Moneycontrol • 4 years ago

Vasundhara Ras Standalone September 2021 Net Sales at Rs 4.15 crore, down 38.26% Y-o-Y

Moneycontrol • 4 years ago

Vasundhara Rasayans resumes partial operations at Mahad plant

Indiainfoline • 5 years ago

Vasundhara Ras Standalone June 2021 Net Sales at Rs 7.17 crore, up 78.03% Y-o-Y

Moneycontrol • 5 years ago

Premium access

Complete news archive for Vasundhara

Full article history, source details, and older brand coverage require an active premium plan.

Full article archive
Source and publication date
Older coverage
Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vasundhara

When was Vasundhara founded?

Vasundhara was founded in 1990.

Where is Vasundhara located?

Vasundhara is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

How many employees does Vasundhara have?

Vasundhara has 36 employees.

What is the annual revenue of Vasundhara?

The primary company behind Vasundhara, Vasundhara Rasayans Limited, reported revenue of ₹38.62 Cr for FY 2026, up 5% year on year.

What does Vasundhara do?

Vasundhara was established in 1990 in Hyderabad, India, within the pharmaceutical sector. Active Pharmaceutical Ingredients (APIs) are produced as the core operation, supporting drug manufacturing processes. The company maintains its base in Hyderabad, where production activities are centered. Online presence is provided through the domain vasundhararasayans.in, facilitating industry connections in the region.

Which companies are similar to Vasundhara?

Vasundhara's top competitors include Laurus Labs, Symbiotec and SeQuent.

Is Vasundhara publicly traded?

Yes, Vasundhara is publicly traded on BSE under the ticker symbol VRL.

Which legal entities are associated with Vasundhara?

Vasundhara operates through Vasundhara Rasayans Limited.

Who are the directors of Vasundhara?

The legal entities of Vasundhara currently have 13 directors, including Seema Jain, Pravinchandra Majmundar Popatlal, Manish Jain and others.